Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in ...
2h
'Biggest pension reforms in a generation' announced - what they actually mean for you | Money blog
Today's Money Problem comes from a couple whose holiday turned into a nightmare when a passport control delay made them miss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results